Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.
AffiliationDepartment of Clinical Pharmacology, Christie Hospital and Holt Radium Institute, M20 9BX Manchester, England.
MetadataShow full item record
AbstractCyclophosphamide (CP) was administered to eight patients with metastatic bronchial carcinoma in escalating doses of 1.5, 2.5, and 3.5 g/m2 at intervals of 3 weeks. The proportion of the administered dose converted into alkylating metabolites was similar for each dose and there was no evidence to suggest that the enzyme system responsible for activating CP was saturated even with the highest dose. Considerable between-patient variation in drug metabolism was observed, but within each patient the fraction metabolised remained constant.
CitationPharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma. 1983, 11 (3):196-9 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology